The Evolution of Chimeric Antigen Receptor T-Cell Therapy in Children, Adolescents and Young Adults with Acute Lymphoblastic Leukemia

Chimeric antigen receptor T-cell (CAR T) therapy is a revolutionary treatment for pediatric, adolescent and young adult patients (AYA) with relapsed/refractory B-cell acute lymphoblastic leukemia. While the landscape of immunotherapy continues to rapidly evolve, widespread use of CAR T therapy is li...

Descripción completa

Detalles Bibliográficos
Autores principales: Ragoonanan, Dristhi, Sheikh, Irtiza N., Gupta, Sumit, Khazal, Sajad J., Tewari, Priti, Petropoulos, Demetrios, Li, Shulin, Mahadeo, Kris M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496125/
https://www.ncbi.nlm.nih.gov/pubmed/36140387
http://dx.doi.org/10.3390/biomedicines10092286
_version_ 1784794191979610112
author Ragoonanan, Dristhi
Sheikh, Irtiza N.
Gupta, Sumit
Khazal, Sajad J.
Tewari, Priti
Petropoulos, Demetrios
Li, Shulin
Mahadeo, Kris M.
author_facet Ragoonanan, Dristhi
Sheikh, Irtiza N.
Gupta, Sumit
Khazal, Sajad J.
Tewari, Priti
Petropoulos, Demetrios
Li, Shulin
Mahadeo, Kris M.
author_sort Ragoonanan, Dristhi
collection PubMed
description Chimeric antigen receptor T-cell (CAR T) therapy is a revolutionary treatment for pediatric, adolescent and young adult patients (AYA) with relapsed/refractory B-cell acute lymphoblastic leukemia. While the landscape of immunotherapy continues to rapidly evolve, widespread use of CAR T therapy is limited and many questions remain regarding the durability of CAR T therapy, methods to avoid CAR T therapy resistance and the role of consolidative stem cell transplant. Modified strategies to develop effective and persistent CAR T cells at lower costs and decreased toxicities are warranted. In this review we present current indications, limitations and future directions of CAR T therapy for ALL in the pediatric and AYA population.
format Online
Article
Text
id pubmed-9496125
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94961252022-09-23 The Evolution of Chimeric Antigen Receptor T-Cell Therapy in Children, Adolescents and Young Adults with Acute Lymphoblastic Leukemia Ragoonanan, Dristhi Sheikh, Irtiza N. Gupta, Sumit Khazal, Sajad J. Tewari, Priti Petropoulos, Demetrios Li, Shulin Mahadeo, Kris M. Biomedicines Review Chimeric antigen receptor T-cell (CAR T) therapy is a revolutionary treatment for pediatric, adolescent and young adult patients (AYA) with relapsed/refractory B-cell acute lymphoblastic leukemia. While the landscape of immunotherapy continues to rapidly evolve, widespread use of CAR T therapy is limited and many questions remain regarding the durability of CAR T therapy, methods to avoid CAR T therapy resistance and the role of consolidative stem cell transplant. Modified strategies to develop effective and persistent CAR T cells at lower costs and decreased toxicities are warranted. In this review we present current indications, limitations and future directions of CAR T therapy for ALL in the pediatric and AYA population. MDPI 2022-09-14 /pmc/articles/PMC9496125/ /pubmed/36140387 http://dx.doi.org/10.3390/biomedicines10092286 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Ragoonanan, Dristhi
Sheikh, Irtiza N.
Gupta, Sumit
Khazal, Sajad J.
Tewari, Priti
Petropoulos, Demetrios
Li, Shulin
Mahadeo, Kris M.
The Evolution of Chimeric Antigen Receptor T-Cell Therapy in Children, Adolescents and Young Adults with Acute Lymphoblastic Leukemia
title The Evolution of Chimeric Antigen Receptor T-Cell Therapy in Children, Adolescents and Young Adults with Acute Lymphoblastic Leukemia
title_full The Evolution of Chimeric Antigen Receptor T-Cell Therapy in Children, Adolescents and Young Adults with Acute Lymphoblastic Leukemia
title_fullStr The Evolution of Chimeric Antigen Receptor T-Cell Therapy in Children, Adolescents and Young Adults with Acute Lymphoblastic Leukemia
title_full_unstemmed The Evolution of Chimeric Antigen Receptor T-Cell Therapy in Children, Adolescents and Young Adults with Acute Lymphoblastic Leukemia
title_short The Evolution of Chimeric Antigen Receptor T-Cell Therapy in Children, Adolescents and Young Adults with Acute Lymphoblastic Leukemia
title_sort evolution of chimeric antigen receptor t-cell therapy in children, adolescents and young adults with acute lymphoblastic leukemia
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496125/
https://www.ncbi.nlm.nih.gov/pubmed/36140387
http://dx.doi.org/10.3390/biomedicines10092286
work_keys_str_mv AT ragoonanandristhi theevolutionofchimericantigenreceptortcelltherapyinchildrenadolescentsandyoungadultswithacutelymphoblasticleukemia
AT sheikhirtizan theevolutionofchimericantigenreceptortcelltherapyinchildrenadolescentsandyoungadultswithacutelymphoblasticleukemia
AT guptasumit theevolutionofchimericantigenreceptortcelltherapyinchildrenadolescentsandyoungadultswithacutelymphoblasticleukemia
AT khazalsajadj theevolutionofchimericantigenreceptortcelltherapyinchildrenadolescentsandyoungadultswithacutelymphoblasticleukemia
AT tewaripriti theevolutionofchimericantigenreceptortcelltherapyinchildrenadolescentsandyoungadultswithacutelymphoblasticleukemia
AT petropoulosdemetrios theevolutionofchimericantigenreceptortcelltherapyinchildrenadolescentsandyoungadultswithacutelymphoblasticleukemia
AT lishulin theevolutionofchimericantigenreceptortcelltherapyinchildrenadolescentsandyoungadultswithacutelymphoblasticleukemia
AT mahadeokrism theevolutionofchimericantigenreceptortcelltherapyinchildrenadolescentsandyoungadultswithacutelymphoblasticleukemia
AT ragoonanandristhi evolutionofchimericantigenreceptortcelltherapyinchildrenadolescentsandyoungadultswithacutelymphoblasticleukemia
AT sheikhirtizan evolutionofchimericantigenreceptortcelltherapyinchildrenadolescentsandyoungadultswithacutelymphoblasticleukemia
AT guptasumit evolutionofchimericantigenreceptortcelltherapyinchildrenadolescentsandyoungadultswithacutelymphoblasticleukemia
AT khazalsajadj evolutionofchimericantigenreceptortcelltherapyinchildrenadolescentsandyoungadultswithacutelymphoblasticleukemia
AT tewaripriti evolutionofchimericantigenreceptortcelltherapyinchildrenadolescentsandyoungadultswithacutelymphoblasticleukemia
AT petropoulosdemetrios evolutionofchimericantigenreceptortcelltherapyinchildrenadolescentsandyoungadultswithacutelymphoblasticleukemia
AT lishulin evolutionofchimericantigenreceptortcelltherapyinchildrenadolescentsandyoungadultswithacutelymphoblasticleukemia
AT mahadeokrism evolutionofchimericantigenreceptortcelltherapyinchildrenadolescentsandyoungadultswithacutelymphoblasticleukemia

Ejemplares similares